AN OPEN LABEL STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF A ONCE NIGHTLY FORMULATION OF SODIUM OXYBATE FOR EXTENDED-RELEASE ORAL SUSPENSION (FT218) AND THE ABILITY TO SWITCH FROM TWICE-NIGHTLY IMMEDIATE RELEASE SODIUM OXYBATE TO ONCE-NIGHTLY FT218 FOR THE TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS AND CATAPLEXY IN SUBJECTS WITH NARCOLEPSY (NCTNCT04451668) - Patient Guide & Enrollment Help